ES2968733T3 - Derivados morfolinilo, piperazinilo, oxazepanilo y diazepanilo útiles como inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa - Google Patents

Derivados morfolinilo, piperazinilo, oxazepanilo y diazepanilo útiles como inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa Download PDF

Info

Publication number
ES2968733T3
ES2968733T3 ES19828102T ES19828102T ES2968733T3 ES 2968733 T3 ES2968733 T3 ES 2968733T3 ES 19828102 T ES19828102 T ES 19828102T ES 19828102 T ES19828102 T ES 19828102T ES 2968733 T3 ES2968733 T3 ES 2968733T3
Authority
ES
Spain
Prior art keywords
methyl
acetamide
thiazol
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19828102T
Other languages
English (en)
Spanish (es)
Inventor
Nathan Genung
Kevin Guckian
Jeffrey Vessels
Lei Zhang
Ryan Gianatassio
Edward Yin Lin
Zhili Xin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Application granted granted Critical
Publication of ES2968733T3 publication Critical patent/ES2968733T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES19828102T 2018-12-05 2019-12-04 Derivados morfolinilo, piperazinilo, oxazepanilo y diazepanilo útiles como inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa Active ES2968733T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862775558P 2018-12-05 2018-12-05
PCT/US2019/064514 WO2020117961A1 (en) 2018-12-05 2019-12-04 Morpholinyl, piperazinyl, oxazepanyl and diazepanyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Publications (1)

Publication Number Publication Date
ES2968733T3 true ES2968733T3 (es) 2024-05-13

Family

ID=69006035

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19828102T Active ES2968733T3 (es) 2018-12-05 2019-12-04 Derivados morfolinilo, piperazinilo, oxazepanilo y diazepanilo útiles como inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa

Country Status (9)

Country Link
US (1) US12319679B2 (enExample)
EP (2) EP3891146B1 (enExample)
JP (1) JP7607562B2 (enExample)
AR (1) AR117252A1 (enExample)
ES (1) ES2968733T3 (enExample)
MA (1) MA54384A (enExample)
TW (1) TW202039482A (enExample)
UY (1) UY38498A (enExample)
WO (1) WO2020117961A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102533471B1 (ko) * 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도
WO2025247394A1 (zh) * 2024-05-31 2025-12-04 纽欧申医药(上海)有限公司 含氮杂环化合物、其药物组合物及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
PT2970272T (pt) * 2013-03-14 2019-06-05 Merck Patent Gmbh Inibidores de glicosidase
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US20190359609A1 (en) 2016-12-16 2019-11-28 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
EP3555087A1 (en) * 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
WO2018154133A1 (en) * 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors

Also Published As

Publication number Publication date
US20220017506A1 (en) 2022-01-20
AR117252A1 (es) 2021-07-21
EP4327814A2 (en) 2024-02-28
JP2022510430A (ja) 2022-01-26
MA54384A (fr) 2021-10-13
WO2020117961A1 (en) 2020-06-11
JP7607562B2 (ja) 2024-12-27
US12319679B2 (en) 2025-06-03
EP4327814A3 (en) 2024-04-24
EP3891146B1 (en) 2023-09-27
UY38498A (es) 2020-07-31
TW202039482A (zh) 2020-11-01
EP3891146A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
JP7626910B2 (ja) Ｒａｆキナーゼの阻害剤
KR102605460B1 (ko) αvβ6 인테그린 억제제
CN112218863B (zh) O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂
US20170334874A1 (en) Piperazine carbamates and methods of making and using same
US20110105459A1 (en) Azetidines and cyclobutanes as histamine h3 receptor antagonists
ES2968733T3 (es) Derivados morfolinilo, piperazinilo, oxazepanilo y diazepanilo útiles como inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
US12122761B2 (en) 2-azaspiro[3.4]octane derivatives as M4 agonists
JP2022551853A (ja) Ｍ４作動薬としての５－オキサ－２－アザスピロ［３．４］オクタン誘導体
US12421224B2 (en) Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
CN117865941B (zh) 取代哌啶化合物及其制备方法和应用
HK40077347A (zh) Raf激酶的抑制剂
HK40077347B (zh) Raf激酶的抑制剂